Abiomed Announces Investor & Analyst Day in New York City on December 9

Agenda to Include Presentations on Recent PROTECT II Data and New Product Updates

DANVERS, Mass.--()--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, will host an investor and analyst day on Friday, December 9, 2011 from 2:00 to 4:30 p.m. at the New York Palace in New York City.

The agenda will include physician presentations, which will discuss the new data from PROTECT II and new product updates. The meeting will also include an overview with Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed, including details on recent quarterly financials and company developments.

Members of the investment community are invited to attend. For more details and to register to attend, please contact Aimee Maillett at (978) 646-1553 or amaillett@abiomed.com.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Contacts

Abiomed
Aimee Maillett, 978-646-1553
Corporate Communications Manager
amaillett@abiomed.com

Contacts

Abiomed
Aimee Maillett, 978-646-1553
Corporate Communications Manager
amaillett@abiomed.com